Using a pre-clinical small-molecule inhibitor of USP15 (USP15-Inh), we evaluated whether pharmacologically inhibiting USP15 DUB activity is a tractable therapeutic approach in AML cells. This evidence concerns the gene USP15 and acute myeloid leukemia.